It is encouraging to note that there are a significant number of clinical trials of anti-PD-1/PD-L1 ongoing, with example lists of phase III–IV trials in lung cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma shown in Table 5. Here, CD274 is linked to hepatocellular carcinoma.